Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease.
Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease.
复制标题
DOI：
10.1053/j.gastro.2021.08.014
复制
发表时间：
2021-12
期刊：
影响因子：
29.4
通讯作者：
Younes Z
中科院分区：
文献类型：
--
作者：
Pozdnyakova V;Botwin GJ;Sobhani K;Prostko J;Braun J;Mcgovern DPB;Melmed GY;Appel K;Banty A;Feldman E;Ha C;Kumar R;Lee S;Rabizadeh S;Stein T;Syal G;Targan S;Vasiliauskas E;Ziring D;Debbas P;Hampton M;Mengesha E;Stewart JL;Frias EC;Cheng S;Ebinger J;Figueiredo JC;Boland B;Charabaty A;Chiorean M;Cohen E;Flynn A;Valentine J;Fudman D;Horizon A;Hou J;Hwang C;Lazarev M;Lum D;Fausel R;Reddy S;Mattar M;Metwally M;Ostrov A;Parekh N;Raffals L;Sheibani S;Siegel C;Wolf D;Younes Z
(新冠肺炎)在美国的预防。其中包括信使RNA(MRNA)平台疫苗(mRNA-1273；莫德纳/国立卫生研究院)和BNT162b2(辉瑞-BioNTech)和腺病毒载体疫苗(AD26)。CoV2。S；强生)，在针对当时流行变种的III阶段注册试验中，它们对新冠肺炎感染的有效率分别为94%、95%和67%。1-3所有3种疫苗都针对病毒尖峰蛋白(S)，该蛋白促进严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过其受体结合域进入宿主细胞。虽然mRNA平台疫苗是间隔3-4周接种的两剂疫苗，但AD26。CoV2。S是单剂给药。另一种腺病毒载体疫苗(ChAdOx1；阿斯利康)尚未在美国获得批准，计划采用两剂方案，间隔8-12周。使用皮质类固醇、免疫调节剂和高级疗法的炎症性肠病(IBD)患者对SARS-CoV-2mRNA疫苗平台的体液反应可能正常或略有下降。1此外，在单剂BNT162b2或ChAdOx1之后，接受英夫利昔单抗和/或硫嘌呤治疗的患者的血清转换率明显低于接受vedolizumab单药治疗的患者。2实体器官移植受者的一项研究显示，AD26的体液反应降低。CoV2。S疫苗相对于两种信使核糖核酸平台疫苗，尽管尚不清楚这些发现是否适用于其他免疫受损人群。4我们的目的是评估服用AD26的IBD患者的血清学反应的差异。CoV2。S相对那些接受mRNA1273或BNT162b2的人。在353名IBD疫苗接受者中，148人(42%)、193人(55%)和12人(3%)分别接种了mRNA1273BNT162b2和AD26mRNA-1273BNT162b2和AD26。CoV2。分别是S。各疫苗组的人口统计和疾病特征相似(平均年龄为51岁，其中62%为女性)(补充表1)。大约290名(83.1%)参与者正在接受免疫调节疗法(IMTS)，定义为在最初接种疫苗时接受了高级疗法(生物制品或JAK抑制剂，80.2%)、免疫调节剂(16.6%)和/或全身皮质类固醇(6.6%)。在疫苗方案完成至少2周后，121名(100%)、142名(99%)和9名(90%)接受mRNA-1273、BNT162b2和AD26的患者检测到阳性抗体水平。CoV2。S，分别为(图1A)。MRNA-1273和BNT162b2的受者在2周(方案完成后14-29天)和8周(方案完成后42-84天)的定量log10(抗Spike IgG)水平均显著高于AD26。CoV2。S(1周：4.20vs3.92vs1.96)至少8周：3.72vs3.41vs2.65；P<；001将每个基因疫苗与AD26进行比较。CoV2。S在每个时间点)(图1B)。我们在疫苗方案完成后的第2周和第8周进行了多变量分析，评估了定量抗体水平，调整了疫苗方案和采血之间的时间、疫苗类型和免疫抑制状态的独立影响。在第2周，只有疫苗类型与抗体水平相关，其中mRNA-1273和BNT162b2的水平都显著高于AD26。CoV2。S(m RNA-1273：B，2.24；95%可信区间，1.80-2.68；P<；00001美元/…
(COVID-19) prevention in the United States. These include the messenger RNA (mRNA) platform vaccines (mRNA-1273; Moderna/National Institutes of Health) and BNT162b2 (Pfizer-BioNTech) and an adenovirus vector vaccine (Ad26. CoV2. S; Johnson & Johnson), which were 94%, 95%, and 67% effective against COVID-19 infection in their phase III registry trials against the endemic variants at the time, respectively. 1–3 All 3 vaccines target the viral spike (S) protein that facilitates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into host cells via its receptor binding domain. Although the mRNA platform vaccines are 2-dose vaccines administered 3–4 weeks apart, the Ad26. CoV2. S is administered as a single dose. Another adenovirus vector vaccine (ChAdOx1; Astrazeneca), not yet authorized in the United States, is intended as a 2-dose regimen with an interval of 8–12 weeks. Patients with inflammatory bowel disease (IBD) on corticosteroids, immunomodulators, and advanced therapies may have normal to slightly decreased humoral responses to the SARS-CoV-2 mRNA vaccine platforms. 1 In addition, patients receiving infliximab and/or thiopurines have significantly lower rates of seroconversion than those on vedolizumab monotherapy after a single dose of either BNT162b2 or ChAdOx1. 2 A study of solid organ transplant recipients showed decreased humoral responses to Ad26. CoV2. S vaccine relative to both mRNA platform vaccines, although it is unknown whether these findings are generalizable to other immune compromised populations. 4 We aimed to assess for differences in serologic responses among patients with IBD who received Ad26. CoV2. S relative to those receiving mRNA-1273 or BNT162b2. Among 353 vaccine recipients with IBD participating in a prospective nationwide SARS-CoV-2 vaccine registry without prior COVID-19 infection and who had completed a full vaccine regimen, 148 (42%), 193 (55%), and 12 (3%) received mRNA-1273, BNT162b2, and Ad26. CoV2. S, respectively. Demographic and disease characteristics were similar across vaccine groups (mean age, 51 years, 62% were female)(Supplementary Table 1). Approximately 290 (83.1%) participants were on immune-modifying therapies (IMTs), as defined by receipt of advanced therapies (biologics or JAK inhibitors, 80.2%), immunomodulators (16.6%), and/or systemic corticosteroids (6.6%) at the time of initial vaccination. At least 2 weeks after completion of the vaccine regimen, positive antibody levels were detected in 121 (100%), 142 (99%), and 9 (90%) patients receiving mRNA-1273, BNT162b2, and Ad26. CoV2. S, respectively (Figure 1A). Quantitative log10 (anti-Spike IgG) levels at both 2 weeks (14–29 days after regimen completion) and 8 weeks (42–84 days after regimen completion) were significantly higher among recipients of mRNA-1273 and BNT162b2 compared with Ad26. CoV2. S (1 weeks: 4.20 vs 3.92 vs 1.96 for mRNA-1273, BNT162b2, and Ad26CoV2. S, respectively; at least 8 weeks: 3.72 vs 3.41 vs 2.65, respectively; P<. 001 comparing each mRNA vaccine with Ad26. CoV2. S at each time point)(Figure 1B). We performed multivariable analysis assessing quantitative antibody levels after weeks 2 and 8 following vaccine regimen completion, adjusting for the independent effects of time between vaccine regimen and blood sampling, vaccine type, and immunosuppression status. At week 2, only vaccine type was associated with antibody levels, with both mRNA-1273 and BNT162b2 having significantly higher levels than Ad26. CoV2. S (mRNA-1273: b, 2.24; 95% confidence interval [CI], 1.80 to 2.68; P<. 00001 …
影响因子：
29.4
作者：
Wong SY;Dixon R;Martinez Pazos V;Gnjatic S;Colombel JF;Cadwell K;ICARUS-IBD Working Group
通讯作者：
ICARUS-IBD Working Group
影响因子：
24.5
作者：
Kennedy, Nicholas A.;Lin, Simeng;Ahmad, Tariq
通讯作者：
Ahmad, Tariq